JP6885968B2 - ブロモドメイン阻害薬としてのピリジンジカルボキサミド誘導体 - Google Patents
ブロモドメイン阻害薬としてのピリジンジカルボキサミド誘導体 Download PDFInfo
- Publication number
- JP6885968B2 JP6885968B2 JP2018561570A JP2018561570A JP6885968B2 JP 6885968 B2 JP6885968 B2 JP 6885968B2 JP 2018561570 A JP2018561570 A JP 2018561570A JP 2018561570 A JP2018561570 A JP 2018561570A JP 6885968 B2 JP6885968 B2 JP 6885968B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- alkyl
- minutes
- methylcarbamoyl
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(*)c1nc(C(N*)=O)cc(C(N*)=O)c1 Chemical compound *C(*)c1nc(C(N*)=O)cc(C(N*)=O)c1 0.000 description 2
- LFUASZAIEOYAFB-MKBNYLNASA-N C[C@@H](c1cncc2c1cc[nH]2)c1nc(C(NC)=O)cc(C(N[C@@H]2[C@@H](C)C2)=O)c1 Chemical compound C[C@@H](c1cncc2c1cc[nH]2)c1nc(C(NC)=O)cc(C(N[C@@H]2[C@@H](C)C2)=O)c1 LFUASZAIEOYAFB-MKBNYLNASA-N 0.000 description 2
- ORTORGVRSOGMJC-UHFFFAOYSA-N CC(C)(C)OC(c1cc(C(NC)=O)nc(C(Br)=C)c1)=O Chemical compound CC(C)(C)OC(c1cc(C(NC)=O)nc(C(Br)=C)c1)=O ORTORGVRSOGMJC-UHFFFAOYSA-N 0.000 description 1
- VYMGXKLJPDSKHN-UHFFFAOYSA-N CC(C)(C)OC(c1cc(C(NC)=O)nc(C(c2ncccc2)O)c1)=O Chemical compound CC(C)(C)OC(c1cc(C(NC)=O)nc(C(c2ncccc2)O)c1)=O VYMGXKLJPDSKHN-UHFFFAOYSA-N 0.000 description 1
- NZRWZHHBEQXSQC-UHFFFAOYSA-N CC(C)(C)OC(c1cc(C=C)nc(C(NC)=O)c1)=O Chemical compound CC(C)(C)OC(c1cc(C=C)nc(C(NC)=O)c1)=O NZRWZHHBEQXSQC-UHFFFAOYSA-N 0.000 description 1
- VYUUVOOPNCGFGM-UHFFFAOYSA-N CC(C)(C)OC(c1cc(Cc(cc2)ccc2OC)nc(C(NC)=O)c1)=O Chemical compound CC(C)(C)OC(c1cc(Cc(cc2)ccc2OC)nc(C(NC)=O)c1)=O VYUUVOOPNCGFGM-UHFFFAOYSA-N 0.000 description 1
- VGUKTEKHFHLCSV-UHFFFAOYSA-N CC(c1ccccc1)c1nc(C(NC)=O)cc(C(NC2CC2)=O)c1 Chemical compound CC(c1ccccc1)c1nc(C(NC)=O)cc(C(NC2CC2)=O)c1 VGUKTEKHFHLCSV-UHFFFAOYSA-N 0.000 description 1
- PUEVBTAMMGYJPN-UHFFFAOYSA-N CC(c1ccccc1)c1nc(C(NC)=O)cc(C(NC2CCC2)=O)c1 Chemical compound CC(c1ccccc1)c1nc(C(NC)=O)cc(C(NC2CCC2)=O)c1 PUEVBTAMMGYJPN-UHFFFAOYSA-N 0.000 description 1
- AMFFVVXTMYOSTQ-UHFFFAOYSA-N CC(c1ncccc1)c1nc(C(NC)=O)cc(C(OC(C)(C)C)=O)c1 Chemical compound CC(c1ncccc1)c1nc(C(NC)=O)cc(C(OC(C)(C)C)=O)c1 AMFFVVXTMYOSTQ-UHFFFAOYSA-N 0.000 description 1
- IILKZTXEEOAMAW-UHFFFAOYSA-N CCC(c1c(cc[nH]2)c2cnc1)c1nc(C(NC)=O)cc(C(O)=O)c1 Chemical compound CCC(c1c(cc[nH]2)c2cnc1)c1nc(C(NC)=O)cc(C(O)=O)c1 IILKZTXEEOAMAW-UHFFFAOYSA-N 0.000 description 1
- JPJKTUCNCYQEEO-UHFFFAOYSA-N CNC(c1cc(C(NC(C2)CC2S(C)=O)=O)cc(Cc2ccccc2)n1)=O Chemical compound CNC(c1cc(C(NC(C2)CC2S(C)=O)=O)cc(Cc2ccccc2)n1)=O JPJKTUCNCYQEEO-UHFFFAOYSA-N 0.000 description 1
- WAIUWPSEUWRUBU-UHFFFAOYSA-N CNC(c1cc(C(NC2CC2)=O)cc(Br)n1)=O Chemical compound CNC(c1cc(C(NC2CC2)=O)cc(Br)n1)=O WAIUWPSEUWRUBU-UHFFFAOYSA-N 0.000 description 1
- GFNFFYQQVRGJMR-UHFFFAOYSA-N CNC(c1cc(C(NC2CC2)=O)cc(Cc2ccccc2)n1)=O Chemical compound CNC(c1cc(C(NC2CC2)=O)cc(Cc2ccccc2)n1)=O GFNFFYQQVRGJMR-UHFFFAOYSA-N 0.000 description 1
- MFUOWKODCCWLJI-BQGOGBDGSA-N CNC(c1cc(C(N[C@@H]([C@@H](CC2)CC2(F)F)C=N)=O)cc(C(c2ccccc2)O)n1)=O Chemical compound CNC(c1cc(C(N[C@@H]([C@@H](CC2)CC2(F)F)C=N)=O)cc(C(c2ccccc2)O)n1)=O MFUOWKODCCWLJI-BQGOGBDGSA-N 0.000 description 1
- YTOHFGDKAYOVAR-UHFFFAOYSA-N CNC(c1cc(C(O)=O)cc(Cc2cccc3c2CCN3C(OCc2ccccc2)=O)n1)=O Chemical compound CNC(c1cc(C(O)=O)cc(Cc2cccc3c2CCN3C(OCc2ccccc2)=O)n1)=O YTOHFGDKAYOVAR-UHFFFAOYSA-N 0.000 description 1
- FIFBITHWXUFYKX-VWDMACCTSA-N C[C@@H](C1)C1NC(C1=CC(Cc2cc(OC)ccc2)NC(C(NC)=O)=C1)=O Chemical compound C[C@@H](C1)C1NC(C1=CC(Cc2cc(OC)ccc2)NC(C(NC)=O)=C1)=O FIFBITHWXUFYKX-VWDMACCTSA-N 0.000 description 1
- ZZMLVZNVSCIVMA-KAKCIXEOSA-N C[C@@H](C1)[C@H]1NC(c1cc(C(NC)=O)nc(C(CC#N)c2ccccc2)c1)=O Chemical compound C[C@@H](C1)[C@H]1NC(c1cc(C(NC)=O)nc(C(CC#N)c2ccccc2)c1)=O ZZMLVZNVSCIVMA-KAKCIXEOSA-N 0.000 description 1
- DEKYMDLVXKZRDH-MRAATUQHSA-N C[C@@H](C1)[C@H]1NC(c1cc(C(NC)=O)nc(C(c2ncccc2)O)c1)=O Chemical compound C[C@@H](C1)[C@H]1NC(c1cc(C(NC)=O)nc(C(c2ncccc2)O)c1)=O DEKYMDLVXKZRDH-MRAATUQHSA-N 0.000 description 1
- IIESWNSIUMPFOF-SGTLLEGYSA-N C[C@@H](C1)[C@H]1NC(c1cc(Cc2cccc3c2CCN3)nc(C(NC)=O)c1)=O Chemical compound C[C@@H](C1)[C@H]1NC(c1cc(Cc2cccc3c2CCN3)nc(C(NC)=O)c1)=O IIESWNSIUMPFOF-SGTLLEGYSA-N 0.000 description 1
- WIUKURQYEWZCBN-NHYWBVRUSA-N C[C@@H](C1)[C@H]1NC(c1cc(Cc2ncccc2)nc(C(NC)=O)c1)=O Chemical compound C[C@@H](C1)[C@H]1NC(c1cc(Cc2ncccc2)nc(C(NC)=O)c1)=O WIUKURQYEWZCBN-NHYWBVRUSA-N 0.000 description 1
- MYPNLZMCDBVNEE-ZDUSSCGKSA-N C[C@@H](COc1cccc(Cc2nc(C(NC)=O)cc(C(NC3CC3)=O)c2)c1)O Chemical compound C[C@@H](COc1cccc(Cc2nc(C(NC)=O)cc(C(NC3CC3)=O)c2)c1)O MYPNLZMCDBVNEE-ZDUSSCGKSA-N 0.000 description 1
- ZDMUOXXRCMHSJC-UHFFFAOYSA-N OB(c1cncc2c1cc[n]2S(c1ccccc1)(=O)=O)O Chemical compound OB(c1cncc2c1cc[n]2S(c1ccccc1)(=O)=O)O ZDMUOXXRCMHSJC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1609096.1 | 2016-05-24 | ||
| GBGB1609096.1A GB201609096D0 (en) | 2016-05-24 | 2016-05-24 | Compounds |
| GBGB1703274.9A GB201703274D0 (en) | 2017-03-01 | 2017-03-01 | Compound |
| GB1703274.9 | 2017-03-01 | ||
| PCT/EP2017/062208 WO2017202742A1 (en) | 2016-05-24 | 2017-05-22 | Pyridine dicarboxamide derivatives as bromodomain inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516761A JP2019516761A (ja) | 2019-06-20 |
| JP2019516761A5 JP2019516761A5 (enExample) | 2020-07-02 |
| JP6885968B2 true JP6885968B2 (ja) | 2021-06-16 |
Family
ID=58739056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561570A Expired - Fee Related JP6885968B2 (ja) | 2016-05-24 | 2017-05-22 | ブロモドメイン阻害薬としてのピリジンジカルボキサミド誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10844015B2 (enExample) |
| EP (1) | EP3464242A1 (enExample) |
| JP (1) | JP6885968B2 (enExample) |
| KR (1) | KR20190006567A (enExample) |
| CN (1) | CN109153646B (enExample) |
| AU (1) | AU2017269673A1 (enExample) |
| BR (1) | BR112018073524A2 (enExample) |
| CA (1) | CA3023765A1 (enExample) |
| RU (1) | RU2018142988A (enExample) |
| WO (1) | WO2017202742A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3344615A1 (en) | 2015-09-02 | 2018-07-11 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
| KR20180052762A (ko) | 2015-09-22 | 2018-05-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 브로모도메인 억제제로서 사용하기 위한 피리디논 디카르복스아미드 |
| RU2018114705A (ru) | 2015-10-05 | 2019-11-07 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Соединения 2-оксо-1,2-дигидропиридин-3,5-дикарбоксамида в качестве ингибиторов бромодомена |
| AU2017245641A1 (en) | 2016-04-07 | 2018-09-13 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridyl derivatives as bromodomain inhibitors |
| CA3023765A1 (en) | 2016-05-24 | 2017-11-30 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pyridine dicarboxamide derivatives as bromodomain inhibitors |
| JOP20190192A1 (ar) | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | مشتقات بيرازول بوصفها مثبطات برومودومين |
| GB201703282D0 (en) * | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
| US10800774B2 (en) | 2017-08-17 | 2020-10-13 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of ATR kinase |
| GB201814167D0 (en) | 2018-08-31 | 2018-10-17 | Glaxosmithkline Ip No 2 Ltd | Compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| ATE438624T1 (de) | 2000-12-28 | 2009-08-15 | Shionogi & Co | 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor |
| DOP2002000332A (es) * | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| PT1477186E (pt) | 2002-02-19 | 2010-02-11 | Shionogi & Co | Antipruriginosos |
| EP1551824B1 (en) * | 2002-10-09 | 2007-12-12 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
| EP1433788A1 (en) | 2002-12-23 | 2004-06-30 | Aventis Pharma Deutschland GmbH | Pyrazole-derivatives as factor Xa inhibitors |
| CN102028994B (zh) | 2003-11-03 | 2013-04-24 | 葛兰素集团有限公司 | 流体分配装置 |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| SG11201503397YA (en) * | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| CN105593224B (zh) * | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 |
| EP3344615A1 (en) * | 2015-09-02 | 2018-07-11 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
| KR20180052762A (ko) | 2015-09-22 | 2018-05-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 브로모도메인 억제제로서 사용하기 위한 피리디논 디카르복스아미드 |
| RU2018114705A (ru) * | 2015-10-05 | 2019-11-07 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Соединения 2-оксо-1,2-дигидропиридин-3,5-дикарбоксамида в качестве ингибиторов бромодомена |
| AU2017245641A1 (en) | 2016-04-07 | 2018-09-13 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridyl derivatives as bromodomain inhibitors |
| CA3023765A1 (en) | 2016-05-24 | 2017-11-30 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pyridine dicarboxamide derivatives as bromodomain inhibitors |
| GB201703282D0 (en) | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
-
2017
- 2017-05-22 CA CA3023765A patent/CA3023765A1/en active Pending
- 2017-05-22 AU AU2017269673A patent/AU2017269673A1/en not_active Abandoned
- 2017-05-22 KR KR1020187037391A patent/KR20190006567A/ko not_active Withdrawn
- 2017-05-22 EP EP17724567.7A patent/EP3464242A1/en not_active Withdrawn
- 2017-05-22 WO PCT/EP2017/062208 patent/WO2017202742A1/en not_active Ceased
- 2017-05-22 BR BR112018073524A patent/BR112018073524A2/pt not_active Application Discontinuation
- 2017-05-22 RU RU2018142988A patent/RU2018142988A/ru not_active Application Discontinuation
- 2017-05-22 CN CN201780032102.3A patent/CN109153646B/zh not_active Expired - Fee Related
- 2017-05-22 US US16/303,211 patent/US10844015B2/en not_active Expired - Fee Related
- 2017-05-22 JP JP2018561570A patent/JP6885968B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190006567A (ko) | 2019-01-18 |
| CA3023765A1 (en) | 2017-11-30 |
| AU2017269673A1 (en) | 2018-11-22 |
| CN109153646A (zh) | 2019-01-04 |
| WO2017202742A1 (en) | 2017-11-30 |
| US10844015B2 (en) | 2020-11-24 |
| JP2019516761A (ja) | 2019-06-20 |
| EP3464242A1 (en) | 2019-04-10 |
| BR112018073524A2 (pt) | 2019-05-28 |
| RU2018142988A (ru) | 2020-06-25 |
| US20190202786A1 (en) | 2019-07-04 |
| CN109153646B (zh) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6885968B2 (ja) | ブロモドメイン阻害薬としてのピリジンジカルボキサミド誘導体 | |
| CN110167935B (zh) | 作为αV整合素抑制剂的3-经取代的丙酸 | |
| JP6532599B2 (ja) | ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド | |
| JP6280573B2 (ja) | ブロモドメイン阻害薬としてのフロピリジン | |
| CN111217797B (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| JP6530773B2 (ja) | ２，３−二置換１−アシル−４−アミノ−１，２，３，４−テトラヒドロキノリン誘導体及びブロモドメイン阻害薬としてのそれらの使用 | |
| JP6954921B2 (ja) | ブロモドメイン阻害薬としてのピリジル誘導体 | |
| CN105492444B (zh) | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 | |
| JP6795588B2 (ja) | ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド | |
| CN116964036A (zh) | Kras g12d抑制剂 | |
| JP6832923B2 (ja) | ブロモドメイン阻害薬としての２−オキソ−１，２−ジヒドロピリジン−３，５−ジカルボキサミド化合物 | |
| CN111212834A (zh) | 作为变构shp2抑制剂的吡啶、吡嗪和三嗪化合物 | |
| TW201443023A (zh) | 作爲ｒｏｃｋ抑制劑之酞□酮及異喹啉酮 | |
| CN116547270A (zh) | 4-(2-氟-4-甲氧基-5-3-(((1-甲基环丁基)甲基)氨基甲酰基)双环[2.2.1]庚-2-基)氨基甲酰基)苯氧基)-1-甲基环己烷-1-甲酸衍生物以及类似化合物作为rxfp1调节剂用于治疗心力衰竭 | |
| WO2024061370A1 (zh) | 嘧啶并环类化合物及其制法和用途 | |
| WO2019000682A1 (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| JP6857254B2 (ja) | ブロモドメイン阻害薬としてのピラゾール誘導体 | |
| CN116802181A (zh) | 作为激酶抑制剂的三唑并吡啶化合物 | |
| CN118843613A (zh) | Rxfp1激动剂 | |
| JP2019513728A (ja) | ブロモドメイン阻害薬としてのベンゾ［ｂ］フラン | |
| JP2020509044A (ja) | ブロモドメイン阻害薬としてのピリジル誘導体 | |
| JP2025536323A (ja) | 縮合二環式化合物ならびにＭｅｒ阻害剤およびＡｘｌ阻害剤としてのその使用 | |
| CN118974059A (zh) | 囊性纤维化跨膜传导调控因子的调节剂 | |
| TW201444828A (zh) | 可作爲溴區結構域蛋白抑制劑之咔唑化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200522 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200522 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210421 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210422 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210513 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6885968 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |